

## Special Issue

# Immunotherapies for Acute Myeloid Leukemia

### Message from the Guest Editor

The immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. T cell activating immunotherapeutic approaches like immune checkpoint inhibition, chimeric antigen receptor T cells (CARs) or bi-specific T cell activating antibodies are becoming increasingly important treatment strategies in different cancer types. In acute myeloid leukemia (AML) after intensive chemotherapy most patients achieve a complete remission, however the overall survival for all AML patients is still relatively low. Immunotherapeutic approaches for AML patients might be options to reduce the relapse rate and therefore improve overall survival. This special issue will focus on immunotherapeutic approaches in AML to begin with on established therapies like the allogeneic stem cell transplantation including new concepts improving the graft versus leukemia effect, but also on new efforts to improve immune responses like adoptive T cell transfer, immune checkpoint inhibition and bi-specific antibodies and CAR-T-cell approaches.

### Guest Editor

Prof. Dr. Jochen Greiner

1. Department of Internal Medicine, Diakonie Hospital Stuttgart, 70176 Stuttgart, Germany
2. Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany

### Deadline for manuscript submissions

closed (20 December 2018)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/13002](https://mdpi.com/si/13002)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)



## About the Journal

### Message from the Editorial Board

*Journal of Clinical Medicine* (ISSN 2077-0383) is an international, peer-reviewed, open access journal dedicated to advancing clinical and preclinical research. Our Editorial Board and staff are committed to delivering cutting-edge, timely, peer-reviewed articles spanning the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and impactful research articles, as well as reviews that are clinically significant and relevant to the full spectrum of medical disciplines. All full texts are archived in PubMed Central and indexed in SCIE (Web of Science), Scopus, PubMed, and other major databases. We invite you to submit your manuscript for publication, as well as join our community as a reviewer or reader online.

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).